Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
Recognized from query: Pfizer Phase 3 trials. Matching terms were moved into the structured fields above when recognized.
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 702 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "Pfizer Phase 3 trials" Clear all
Completed Phase 3 Interventional Results available

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

NCT00471146
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
AG-013736, Gemcitabine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
77
States / cities
Antioch, California • Corona, California • Glendora, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

NCT00312494
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
66
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

NCT00421954
View directory record Official record
Conditions
Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Topical Ibuprofen for Delayed Onset Mulscle Soreness

NCT01794923
View directory record Official record
Conditions
Pain
Interventions
IBU BID, Placebo BID, IBU TID, Placebo TID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

NCT00143286
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Santa Ana, California • West Palm Beach, Florida • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2007 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.

NCT00171366
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine/benazepril
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,422 participants
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

NCT02504294
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Epoetin Hospira Arm, Standard of Care Arm, IV Iron
Biological · Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
42
States / cities
Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

NCT03579459
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile vaccine, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
1,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Redding, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

NCT00754013
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (Donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study in Adult and Adolescent Participants With SCD

NCT05431088
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
24
States / cities
New Haven, Connecticut • Plantation, Florida • West Palm Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280
View directory record Official record
Conditions
Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of Care, Macugen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

NCT00232141
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

NCT00355589
View directory record Official record
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Exercise to Treat Depression in Individuals With Coronary Heart Disease

NCT00302068
View directory record Official record
Conditions
Depression, Heart Diseases
Interventions
Supervised Aerobic Exercise, Sertraline, Placebo Pill.
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

NCT00001017
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

NCT00847613
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jul 22, 2026, 2:26 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

NCT07226882
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 44 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
6
States / cities
Warren Township, New Jersey • Cortland, New York • Horseheads, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients

NCT00002140
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Berkeley, California • Mill Valley, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Jul 22, 2026, 2:26 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
10
States / cities
Jupiter, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

NCT04029480
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to ertugliflozin 15 mg, Placebo to ertugliflozin 5 mg, Insulin, Metformin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

NCT03573882
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Little Rock, Arkansas • Oakland, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jul 22, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

NCT01463306
View directory record Official record
Conditions
Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 66 Years
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
21
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 22, 2026, 2:26 PM EDT